Development of a SARS‐CoV‐2 rapid antibody detection kit and study on dynamic changes in antibodies in infected patients

Li, Xuemei; Li, Tao; Wang, Lianzi; Wang, Li; Lin, Jiawang; Zhang, Shubing; Xu, Yuanhong; Wei, Wei

doi:10.1111/crj.13331

Cited by 5 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the following two individuals performed the test using the visual colorimetric method. Wang et al ( Wang et al, 2021a ) designed a colloidal gold immunoassay kit for the detection of two antibodies, IgM and IgG, to the SARS-CoV-2 N protein. The colloidal gold of their test strips was modified with SARS-CoV-2 N antigen obtained from the expression system of pCMVp-NEO-BAN vector + HEK293 cells, and mouse anti-human IgM and IgG were immobilized on the NC membrane.…”

Section: Lfia Technique For Sars-cov-2 Antibody Detectionmentioning

confidence: 99%

Rapid detection of SARS-CoV-2: The gradual boom of lateral flow immunoassay

Zhu

Zhou

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is still in an epidemic situation, which poses a serious threat to the safety of people and property. Rapid diagnosis and isolation of infected individuals are one of the important methods to control virus transmission. Existing lateral flow immunoassay techniques have the advantages of rapid, sensitive, and easy operation, and some new options have emerged with the continuous development of nanotechnology. Such as lateral flow immunoassay test strips based on colorimetric-fluorescent dual-mode and gold nanoparticles, Surface Enhanced Raman Scattering, etc., these technologies have played an important role in the rapid diagnosis of COVID-19. In this paper, we summarize the current research progress of lateral flow immunoassay in the field of Severe Acute Respiratory Syndrome Coronavirus 2 infection diagnosis, analyze the performance of Severe Acute Respiratory Syndrome Coronavirus 2 lateral flow immunoassay products, review the advantages and limitations of different detection methods and markers, and then explore the competitive CRISPR-based nucleic acid chromatography detection method. This method combines the advantages of gene editing and lateral flow immunoassay and can achieve rapid and highly sensitive lateral flow immunoassay detection of target nucleic acids, which is expected to be the most representative method for community and clinical point-of-care testing. We hope that researchers will be inspired by this review and strive to solve the problems in the design of highly sensitive targets, the selection of detection methods, and the enhancement of CRISPR technology, to truly achieve rapid, sensitive, convenient, and specific detection of novel coronaviruses, thus promoting the development of novel coronavirus diagnosis and contributing our modest contribution to the world’s fight against epidemics.

show abstract

Section: Lfia Technique For Sars-cov-2 Antibody Detectionmentioning

confidence: 99%

Rapid detection of SARS-CoV-2: The gradual boom of lateral flow immunoassay

Zhu

Zhou

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…In addition, the titers of SARS‐CoV‐2 targeted IgG as well as IgM antibodies from positive samples increased with time of admission, with the positivity rate for both antibodies increasing from 50% to 92.5%. 87 …”

Section: Antigen–antibody‐based Serological Sars‐cov ...mentioning

confidence: 99%

An updated review of SARS‐CoV‐2 detection methods in the context of a novel coronavirus pandemic

Zhang

Huang

Zhu

et al. 2022

Bioengineering & Transla Med

View full text Add to dashboard Cite

The World Health Organization has reported approximately 430 million confirmed cases of coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), worldwide, including nearly 6 million deaths, since its initial appearance in China in 2019. While the number of diagnosed cases continues to increase, the need for technologies that can accurately and rapidly detect SARS‐CoV‐2 virus infection at early phases continues to grow, and the Federal Drug Administration (FDA) has licensed emergency use authorizations (EUAs) for virtually hundreds of diagnostic tests based on nucleic acid molecules and antigen–antibody serology assays. Among them, the quantitative real‐time reverse transcription PCR (qRT‐PCR) assay is considered the gold standard for early phase virus detection. Unfortunately, qRT‐PCR still suffers from disadvantages such as the complex test process and the occurrence of false negatives; therefore, new nucleic acid detection devices and serological testing technologies are being developed. However, because of the emergence of strongly infectious mutants of the new coronavirus, such as Alpha (B.1.1.7), Delta (B.1.617.2), and Omicron (B.1.1.529), the need for the specific detection of mutant strains is also increasing. Therefore, this article reviews nucleic acid‐ and antigen–antibody‐based serological assays, and compares the performance of some of the most recent FDA‐approved and literature‐reported assays and associated kits for the specific testing of new coronavirus variants.

show abstract

“…It can detect whole blood, serum, and plasma with a simple operation (no professional equipment and professional technicians are required), fast detection speed (10–15 min in the whole process), and low cost. To date, blood-based diagnostic tests, such as rapid detection of antiviral antibodies or viral antigens, have been widely used in many clinical laboratories. − Considering all the advantages of this new test, it has the potential to become an auxiliary diagnostic method for the treatment of COVID-19 and has excellent potential in containing the global pandemic.…”

Section: Introductionmentioning

confidence: 99%

“…To date, blood-based diagnostic tests, such as rapid detection of antiviral antibodies or viral antigens, have been widely used in many clinical laboratories. 14 − 16 Considering all the advantages of this new test, it has the potential to become an auxiliary diagnostic method for the treatment of COVID-19 and has excellent potential in containing the global pandemic.…”

Section: Introductionmentioning

confidence: 99%

Development and Evaluation of a Rapid Neutralizing Antibody Assay for COVID-19 Vaccination

Liu

Yue

et al. 2022

ACS Omega

View full text Add to dashboard Cite

SARS-CoV-2 neutralizing antibodies have excellent application prospects in the prevention and treatment of COVID-19. This study established a competitive colloidal gold immunochromatography assay (GICA) to detect neutralizing antibodies against the receptor-binding domain (RBD) of SARS-CoV-2 in postvaccination serum. The sensitivity, stability, and specificity of GICA were evaluated using neutralizing antibody solution reference material and positive serum. The consistency and correlation between GICA, pseudovirus neutralization (PN) assay, and ELISA were compared. Consistency analysis of serum neutralizing antibody and specific IgG antibody titers was conducted, and changes in neutralizing antibodies and specific IgG antibodies in serum after inoculation with the homologous booster inactivated vaccine and recombinant vaccine were noted. The sensitivity of the reagent was 20.66 IU/L, and the specificity was 100%. There was a strong consistency and correlation between GICA and PN (κ = 0.886, n = 165; r = 0.918, P < 0.001). The correlation coefficient of serum anti-RBD antibody and specific IgG antibody titers was 0.5253 (P < 0.001). The specific IgG antibody titers in serum after (W4) inoculation with homologous booster inactivated vaccine were 10.80 (S/CO).The anti-RBD antibody titers were 28.33. The anti-RBD omicron variant (B.1.1.529) antibody titers were 11.67. After inoculation with the recombinant vaccine, the specific IgG antibody titers in the serum of W4 were 10.68. The serum anti-RBD antibody titers of W4 were 103.30. The serum anti-RBD omicron variant (B.1.1.529) antibody titers of W4 were 56.67. Therefore, vaccination of the third dose of the homologous booster inactivated vaccine and recombinant vaccine can enhance the level of neutralizing antibodies against the omicron variant (B.1.1.529). This study demonstrates that a GICA kit for neutralizing antibodies against the RBD of SARS-CoV-2 can be used for COVID-19 vaccine evaluation. Changes in titers enable long-term monitoring of a population's immunity and guide interventions when their immunity declines.

show abstract

Development of a SARS‐CoV‐2 rapid antibody detection kit and study on dynamic changes in antibodies in infected patients

Cited by 5 publications

References 15 publications

Rapid detection of SARS-CoV-2: The gradual boom of lateral flow immunoassay

Rapid detection of SARS-CoV-2: The gradual boom of lateral flow immunoassay

An updated review of SARS‐CoV‐2 detection methods in the context of a novel coronavirus pandemic

Development and Evaluation of a Rapid Neutralizing Antibody Assay for COVID-19 Vaccination

Contact Info

Product

Resources

About